Dianthus Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $193 | $1,163 | $1,326 | $2,172 |
Gross Profit | 94 | 1,163 | 1,326 | 2,172 |
EBITDA | -34,927 | -33,044 | -31,838 | -29,784 |
EBIT | -35,026 | -33,177 | -31,916 | -29,900 |
Net Income | -31,629 | -29,511 | -28,440 | -25,174 |
Net Change In Cash | 193 | 1,163 | 1,326 | 2,172 |
Free Cash Flow | -23,938 | -27,654 | -27,475 | -21,292 |
Cash | 13,237 | 10,116 | 22,792 | 33,671 |
Basic Shares | 35,822 | 35,791 | 35,033 | 34,236 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $6,235 | $2,826 | $6,417 | $1,476 |
Gross Profit | 6,235 | 2,826 | 6,270 | -544 |
EBITDA | -101,452 | -47,819 | -29,558 | -69,116 |
EBIT | -101,864 | -48,174 | -29,705 | -71,136 |
Net Income | -84,969 | -43,555 | -28,476 | -13,109 |
Net Change In Cash | 6,235 | 2,826 | 6,417 | 1,476 |
Free Cash Flow | -78,285 | -36,971 | -29,209 | -9,937 |
Cash | 22,792 | 132,325 | 15,365 | 7,638 |
Basic Shares | 33,314 | 5,153 | 3,747 | 3,434 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.88 |
2025-03-31 | -$0.82 |
2024-12-31 | -$0.81 |
2024-09-30 | -$0.72 |
